Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.